Table 1 Patients’ characteristics (n = 454)
From: Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer
Age at radical prostatectomy (years) | |
Mean/±SD/median/IQR | 65.3/6.7/66.0/61.0–70.0 |
PSA at radical prostatcetomy (ng/ml) | |
Mean/±SD/median/IQR | 13.8/24.4/8.6/5.6–14.4 |
Gleason score at biopsy (n) | |
% (n/total) | |
8–10 | 25.9 (118/454) |
7 | 62.3 (283/454) |
6 | 11.7 (53/454) |
Gleason score at radical prostatectomy (n) | |
% (n/total) | |
8–10 | 21.2 (96/454) |
7 | 60.6 (275/454) |
6 | 18.3 (83/454) |
T stage at biopsy (n) | |
% (n/total) | |
4 | 1.9 (9/454) |
3 | 36.8 (167/454) |
2 | 61.2 (278/454) |
T stage at radical prostatectomy (n) | |
% (n/total) | |
4 | 0.7 (3/454) |
3 | 34.8 (158/454) |
2 | 64.3 (292/454) |
CAPRA score at biopsy (n) | |
% (n/total) | |
6–10 (high risk) | 41.4 (188/454) |
3–5 (intermediate risk) | 39.8 (181/454) |
1–2 (low risk) | 18.5 (85/454) |
Positive lymph nodes (N+) at radical prostatectomy (n) | |
% (n/total) | 21.3 (97/545) |
Positive surgical margin (R+) at radical prostatectomy (n) | |
% (n/total) | 29.3 (133/454) |